3 days Ago By ABMN Staff
Femasys Inc. ( NASDAQ:FEMY – Free Report ) – Equities research analysts at Chardan Capital cut their FY2024 earnings per share estimates for shares of Femasys in a report released on Wednesday, November 13th. Chardan Capital analyst K.
Nakae now anticipates that the company will earn ($0.84) per share for the year, down from their prior forecast of ($0.79).
Chardan Capital has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Femasys’ current full-year earnings is ($0.
84) per share. Chardan Capital also issued estimates for Femasys’ FY2025 earnings at ($0.49) EPS.
Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Femasys in a report on Tuesday, November 12th. Femasys Trading Down 4.
9 % Femasys stock opened at $0.89 on Monday. Femasys has a 52-week low of $0.
73 and a 52-week high of $2.40. The company has a quick ratio of 3.
26, a current ratio of 3.94 and a debt-to-equity ratio of 0.86.
The firm has a market capitalization of $20.29 million, a price-to-earnings ratio of -1.09 and a beta of -2.
83. The firm has a 50-day moving average price of $1.15 and a two-hundred day moving average price of $1.
14. Femasys ( NASDAQ:FEMY – Get Free Report ) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.
24) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.04).
Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%.
The firm had revenue of $0.55 million for the quarter, compared to the consensus estimate of $0.40 million.
Institutional Investors Weigh In On Femasys Institutional investors have recently bought and sold shares of the stock. Aljian Capital Management LLC acquired a new position in Femasys during the 3rd quarter valued at about $27,000. XTX Topco Ltd boosted its holdings in shares of Femasys by 123.
9% in the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after acquiring an additional 18,004 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Femasys by 9.
2% during the third quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock valued at $229,000 after acquiring an additional 17,473 shares during the period. Finally, CM Management LLC increased its stake in shares of Femasys by 6.
3% during the second quarter. CM Management LLC now owns 425,000 shares of the company’s stock valued at $484,000 after acquiring an additional 25,000 shares during the period. Institutional investors and hedge funds own 65.
27% of the company’s stock. Femasys Company Profile ( Get Free Report ) Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.
Recommended Stories Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter ..
